{"nct_id":"NCT02655224","title":"A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids","status":"COMPLETED","status_verified_date":"2018-12","start_date":"2016-03-26","start_date_type":"ACTUAL","primary_completion_date":"2017-05-16","primary_completion_date_type":"ACTUAL","completion_date":"2017-05-19","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["TAK"]}